Recently, the 5th Yangtze River Delta Biomedical Innovation and Entrepreneurship Competition kicked off in Yancheng, Jiangsu. 30 hardcore scientific and technological innovation projects from the biopharmaceutical field across the country have emerged from over 700 registered teams and staged a "divine fight" in the fields of medical devices, gene therapy, AI medicine, etc., showcasing their respective talents. In the end, Ankai Life Technology's "Innovative Plasma Multi omics Detection Technology and Industrial Application Project" passed all the way and finally ushered in a shining moment, winning both the "Special Award" and the "Most Investment Value Award"!
This competition is jointly organized by Jiangsu Medical and Health Industry Alliance, Shanghai Health Industry Promotion Association, Zhejiang Health Service Industry Promotion Association, and Anhui Health Culture Tourism Industry Promotion Association. Its aim is to integrate the advantages of various resources through multi-party collaboration, and to develop a more complete and efficient ecosystem for the innovative development of the biopharmaceutical industry from the perspective of the entire industry chain.
Since the launch of the competition, it has received enthusiastic responses and active participation from medical institutions, universities, and research and development institutions. More than 700 eligible registration projects have been recommended by the three provinces and one city in the Yangtze River Delta. Ankai Life Science and Technology is deeply involved in the field of early screening for tumors. With its innovative plasma multi omics detection technology and industrial application project, it achieved the highest score of 92 in the competition and won the special prize and the most valuable investment award!
This project directly addresses two core pain points in the field of early screening for tumors: the high risk of traditional invasive screening, which makes screening difficult to popularize; Although the emerging liquid biopsy technology is safe and non-invasive, its high sequencing price has become a barrier to universal promotion.
Angkai's innovative "Plasma Multi omics Innovative Detection Technology and Industrial Application Project" integrates methylation and fragment omics technologies, achieving high-precision and broad-spectrum early screening through single tube blood samples, and solving the core problems of "safety" and "accuracy". At the same time, through independent research and technological innovation of core materials, the project effectively reduces costs and increases efficiency, significantly improves product accessibility, and effectively breaks through the problem of "universality". This project has built an innovative solution that is truly suitable for large-scale population screening, based on the three elements of "safety and reliability, trustworthy technology, and affordable price"!
Expert message
Vice Chairman of Huangjinlin Jiangsu Medical and Health Industry Alliance and Chairman of the Yangtze River Delta Cell Industry Chain Special Committee
Ankai Life Technology's "Innovative Detection Technology and Industrial Application Project of Plasma Multi omics" won the highest honor and special prize of this competition, and was also awarded the Most Valuable Investment Award! This "dual" honor is well deserved and fully reflects the high recognition of our jury for this project.
Early screening of tumors is a major demand related to the national economy and people's livelihood, but technological bottlenecks still exist. This project closely follows the pulse of industry development, focuses on industry pain points and issues, and has a cutting-edge and leading technological direction. Based on the plasma multi omics framework, Angkai innovatively integrates the two technologies of "fragment group" and "methylation" to achieve the detection of cfDNA four dimensional markers: quantity, shape, sequence, and source. It comprehensively utilizes cfDNA tumor marker information, significantly improving the accuracy of tumor early screening and effectively reducing the risk of false positives and false negatives.
The Angkai team is not only at the forefront of technology, but also has a clear understanding of the key to industrialization - cost control and accessibility. They continue to strive for breakthroughs in core materials and the localization of the entire product chain to achieve cost reduction and efficiency improvement, while avoiding the risk of being "choked" by foreign raw materials. This comprehensive consideration and product design make the future commercialization prospects not only promising, but also have the potential to steadily double returns and fully reflect investment value. If the cost of high-performance cancer early screening products is too high, it will be difficult to benefit a wider population, and their social value will be greatly reduced. However, highly accessible products will receive high attention from the government and various sectors of society. Angkai has demonstrated its profound understanding and pragmatic attitude towards the final market-oriented implementation of products by tackling costs from the source materials. This lays a solid foundation for achieving the unity of high performance and universality in the future of the project.
This project perfectly aligns with the purpose of the competition, which is to promote the transformation of innovative achievements, serve industry development, and benefit people's health. Therefore, winning the double recognition of the Grand Prize and the Most Valuable Investment Award is highly anticipated!
About the Yangtze River Delta Biomedical Innovation and Entrepreneurship Competition
The biopharmaceutical industry is not only an important component of the emerging industries in the Yangtze River Delta, but also an important strategic industry related to national economy and people's livelihood. In today's era, with the rapid development of technology, cutting-edge technologies such as biotechnology, information technology, and artificial intelligence are deeply integrated with the field of life and health, bringing unprecedented opportunities and challenges to the innovative development of the biopharmaceutical industry. The 5th Yangtze River Delta Biomedical Innovation and Entrepreneurship Competition was born in this context, becoming an important platform and brand event for the innovative development of the life and health industry in the Yangtze River Delta region.
Through this competition, we will effectively promote more excellent projects to take root and bear fruit in the Yangtze River Delta region, achieving deep integration and coordinated development of industry, academia, research and application; It will also stimulate more cross-border cooperation and innovative thinking collisions, allowing different sub sectors of life and health to blend and promote each other, and jointly create new engines and highlights for the economic development of the Yangtze River Delta.
The Presidium of the Yangtze River Delta Health Industry Alliance stated that they will continue to work together and take this competition as an opportunity to strive for the vigorous development of the biopharmaceutical industry in the Yangtze River Delta, and jointly paint a magnificent picture of the prosperity of the biopharmaceutical industry.